Pharmacokinetic Analysis of a Hemodialyzed Patient Treated With Pazopanib.
Department of Pharmacy, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Satoshi
S
Noda
Department of Pharmacy, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Daiki
D
Hira
Department of Urology, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Susumu
S
Kageyama
Department of Urology, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Fumiyasu
F
Jo
Department of Urology, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Akinori
A
Wada
Department of Urology, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Tetsuya
T
Yoshida
Department of Urology, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Akihiro
A
Kawauchi
Department of Pharmacy, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan.
Shin-Ya
SY
Morita
Department of Pharmacy, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Otsu City, Shiga, Japan. Electronic address: teradat@belle.shiga-med.ac.jp.
Tomohiro
T
Terada
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D011743:Pyrimidines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000379:methods; D013449:Sulfonamides / Q000493:pharmacokinetics* / Q000627:therapeutic use*
D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib
Chronic kidney disease; Hemodialysis; Onco-nephrology; Renal cell carcinoma; Tyrosine kinase inhibitor